NCT00671736View on ClinicalTrials.gov

Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Cystic Fibrosis
Interventions
DRUG

Moli1901

2,5 ml inhalation solution, 8 weeks treatment period

DRUG

Moli1901 placebo

2,5 ml placebo solution, 8 weeks treatment period

Trial Locations (1)

8086

Medical University, Graz

Sponsors
All Listed Sponsors
lead

AOP Orphan Pharmaceuticals AG

INDUSTRY

NCT00671736 - Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis | Biotech Hunter | Biotech Hunter